Vantage Esmo 2019 roundup

Parps show more promise in ovarian and prostate cancers, but Kras disappoints. Here's a round up of Vantage's coverage of the 2019 European Society for Medical Oncology congress.


Esmo 2019 makes for a disappointing read-across to biotech

2 October

An analysis of stock market movers during the period of this year’s Esmo congress gives biotech watchers little cause for happiness.


Clovis is running out of waves to catch

1 October

In prostate cancer Clovis could be adopting a more realistic regulatory stance with its Parp than Astrazeneca and Merck & Co. In the long run will it matter much?


PD-L1 status moves centre stage in bladder cancer

30 September

Roche’s Imvigor-130 study supports Tecentriq’s continued use in urothelial bladder cancer – up to a point.


Targeted bile duct treatment pits Incyte against Agios

30 September

The rare disease bile duct cancer is set to be carved up by genetic subtype, and will see two targeted treatments filed soon.


A place for Parps in prostate cancer

30 September

Lynparza looks set to add a third tumour type to its label, strengthening the grip of Astrazeneca and Merck & Co on the Parp inhibitor market.


Foundation eyes liquid biopsy rule change

30 September

New data could change liquid biopsy guidelines and boost sales, though regulatory approval would not be a bad idea.


Mesothelioma trials contend with super-fast disease progression

30 September

A surprisingly successful study of Opdivo and Yervoy suggests that the enrolment of co-called hyperprogressors could have scuppered other trials.


Pfizer’s Beacon presents a doublet vs triplet conundrum

30 September


Keynote-522 stokes adjuvant hopes for Keytruda

29 September

The triple-negative breast cancer trial backs neoadjuvant Keytruda, but it might prove hard to rule out the benefit of its adjuvant use too.


Thyroid results strengthen selpercatinib's case

29 September

As selpercatinib confirms its activity in thyroid cancer, Lilly gears up to prove the Ret inhibitor’s potential in larger trials.


Abbvie’s Parp underwhelms in breast cancer

29 September


Breast cancer verdict brings G1 down to earth

29 September


Kras springs a leak

28 September

Amgen’s AMG 510 disappoints Kras bulls, showing just two new partial responses, in colorectal and appendiceal tumours.


Glaxo’s Parp ambitions get a boost

28 September

The Prima trial delivers a convincing win for Glaxosmithkline’s Parp inhibitor Zejula, which looks to have a good chance of winning a broader label in ovarian cancer.


Lynparza pushes Parps forward again

28 September

The Paola-1 study of Astrazeneca and Merck & Co’s Lynparza plus Avastin shows that more ovarian cancer patients can benefit from Parp inhibition, though the role of the Roche antibody is less clear.


Too little too late for Abbvie and veliparib?

28 September

Abbvie has finally scored a win with its Parp inhibitor, but the product will struggle to make headway – assuming it will even be filed.


Opdivo could have done better in liver cancer

27 September

A post-mortem of Bristol’s first-line trial suggests that patients’ PD-L1 status should have been taken into consideration, though Roche hopes it too can do without such preselection.


Esmo 2019 preview – immunotherapies grab the rest of the late-breaker focus

10 September

Away from the main small-molecule focus of this year’s Esmo meeting, Keytruda flies the flag for immuno-oncology, including in a little-noticed mesothelioma study.


Esmo 2019 preview – Parps on parade

5 September

Among small-molecule approaches Europe’s premier oncology conference gives star billing to three Parp inhibitors in ovarian cancer.

Related Topics

Share This Article